Trial Profile
Use-results survey for Lonsurf combination tablet T15 & Lonsurf combination tablet T20
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2021
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiho Pharmaceutical Company
- 30 Apr 2021 Status changed from active, no longer recruiting to completed.
- 30 Apr 2021 Results published in the Japanese Journal of Clinical Oncology
- 09 Aug 2016 Status changed from recruiting to active, no longer recruiting.